{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:57:01Z","timestamp":1793872621100,"version":"4.6.1"},"reference-count":206,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009750","name":"University of Rochester Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.anai.2024.06.020","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T06:33:31Z","timestamp":1718951611000},"page":"262-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Atopic dermatitis and IgE-mediated food allergy"],"prefix":"10.1016","volume":"133","author":[{"given":"H. Mark","family":"Kenney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-667X","authenticated-orcid":false,"given":"Lisa A.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.anai.2024.06.020_bib0002","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpeds.2022.04.027","article-title":"The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study","volume":"246","author":"Barbarot","year":"2022","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0003","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"10023","key":"10.1016\/j.anai.2024.06.020_bib0004","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0005","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jaci.2019.01.003","article-title":"Report from the National Institute of Allergy and Infectious Diseases workshop on \"Atopic dermatitis and the atopic march: mechanisms and interventions\"","volume":"143","author":"Davidson","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0006","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.anai.2017.10.037","article-title":"The atopic march: critical evidence and clinical relevance","volume":"120","author":"Hill","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0007","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jaad.2023.11.013","article-title":"Risk of atopic dermatitis and the atopic march paradigm in children of mothers with atopic illnesses: a birth cohort study from the United Kingdom","volume":"90","author":"Chiesa Fuxench","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0008","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/ACI.0000000000000638","article-title":"Atopic dermatitis and its relation to food allergy","volume":"20","author":"Graham","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0009","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1164\/rccm.202210-2022LE","article-title":"IgE sensitization drives the atopic march","volume":"207","author":"Beck","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/jid.2013.298","article-title":"Atopic dermatitis and disease severity are the main risk factors for food sensitization in exclusively breastfed infants","volume":"134","author":"Flohr","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.anai.2024.06.020_bib0011","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/cea.14189","article-title":"Early-onset atopic dermatitis and food hypersensitivity increase the risk of atopic march","volume":"52","author":"Pesonen","year":"2022","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0012","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1542\/peds.101.3.e8","article-title":"Prevalence of IgE-mediated food allergy among children with atopic dermatitis","volume":"101","author":"Eigenmann","year":"1998","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0013","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-1235","article-title":"The public health impact of parent-reported childhood food allergies in the United States","volume":"142","author":"Gupta","year":"2018","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.anai.2024.06.020_bib0014","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1111\/all.15902","article-title":"EAACI guidelines on the diagnosis of IgE-mediated food allergy","volume":"78","author":"Santos","year":"2023","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0015","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jaci.2022.10.023","article-title":"Novel insights into atopic dermatitis","volume":"151","author":"Schuler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"3 Pt 2","key":"10.1016\/j.anai.2024.06.020_bib0016","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/jid.2011.435","article-title":"Skin barrier disruption: a requirement for allergen sensitization?","volume":"132","author":"De Benedetto","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2021.11.006","article-title":"Skin barrier defects in atopic dermatitis: from old idea to new opportunity","volume":"71","author":"Yoshida","year":"2022","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0018","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2340\/0001555565102105","article-title":"Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis","volume":"65","author":"Werner","year":"1985","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0019","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.anai.2024.06.020_bib0020","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.jid.5700739","article-title":"Filaggrin mutations in children with severe atopic dermatitis","volume":"127","author":"Morar","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0021","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/jcm10020233","article-title":"Filaggrin loss-of-function mutations are risk factors for severe food allergy in children with atopic dermatitis","volume":"10","author":"Astolfi","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0022","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaci.2022.05.018","article-title":"Filaggrin loss-of-function mutations are associated with persistence of egg and milk allergy","volume":"150","author":"Kalb","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.07.033","article-title":"Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence","volume":"134","author":"Venkataraman","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100131","article-title":"Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis","volume":"2","author":"Beck","year":"2022","journal-title":"JID Innov"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jid.2015.11.007","article-title":"Influence of Th2 cytokines on the cornified envelope, tight junction proteins, and \u00df-defensins in filaggrin-deficient skin equivalents","volume":"136","author":"H\u00f6nzke","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0026","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","article-title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6","volume":"126","author":"Kim","year":"2008","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2024.06.020_bib0027","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1194\/jlr.P030338","article-title":"Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients","volume":"53","author":"Janssens","year":"2012","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0028","doi-asserted-by":"crossref","first-page":"e98006","DOI":"10.1172\/jci.insight.98006","article-title":"Lipid abnormalities in atopic skin are driven by type 2 cytokines","volume":"3","author":"Berdyshev","year":"2018","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.anai.2024.06.020_bib0029","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1111\/all.15432","article-title":"Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis","volume":"77","author":"Berdyshev","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0030","doi-asserted-by":"crossref","first-page":"AB5","DOI":"10.1016\/j.jaci.2023.11.039","article-title":"Dupilumab improves skin lipid barrier in pediatric patients with moderate-to-severe atopic dermatitis","volume":"153","author":"Bronova","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"1-2","key":"10.1016\/j.anai.2024.06.020_bib0031","doi-asserted-by":"crossref","DOI":"10.4161\/21688370.2014.974451","article-title":"Epidermal tight junctions in health and disease","volume":"3","author":"Brandner","year":"2015","journal-title":"Tissue Barriers"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.10.018","article-title":"Tight junction defects in patients with atopic dermatitis","volume":"127","author":"De Benedetto","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0033","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41598-020-58718-9","article-title":"Claudin-1 decrease impacts epidermal barrier function in atopic dermatitis lesions dose-dependently","volume":"10","author":"Bergmann","year":"2020","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.anai.2024.06.020_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161759","article-title":"Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17","volume":"11","author":"Yuki","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0035","doi-asserted-by":"crossref","first-page":"40.e11","DOI":"10.1111\/vde.12276","article-title":"A comparative study of epidermal tight junction proteins in a dog model of atopic dermatitis","volume":"27","author":"Kim","year":"2016","journal-title":"Vet Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0036","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jdermsci.2014.11.007","article-title":"Epidermal tight junction barrier function is altered by skin inflammation, but not by filaggrin-deficient stratum corneum","volume":"77","author":"Yokouchi","year":"2015","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0037","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/ced.14380","article-title":"Scratching damages tight junctions through the Akt-claudin 1 axis in atopic dermatitis","volume":"46","author":"Hu","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0038","doi-asserted-by":"crossref","first-page":"8625","DOI":"10.1038\/s41598-019-44866-0","article-title":"Homeostatic pruning and activity of epidermal nerves are dysregulated in barrier-impaired skin during chronic itch development","volume":"9","author":"Takahashi","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.anai.2024.06.020_bib0039","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/nu14091893","article-title":"Intestinal barrier permeability in allergic diseases","volume":"14","author":"Niewiem","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0016-5085(89)90767-1","article-title":"Lactulose\/mannitol test: an ideal screen for celiac disease","volume":"96","author":"Juby","year":"1989","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0041","first-page":"87","article-title":"The intestinal permeability test applied to the diagnosis of food allergy in paediatrics","volume":"43","author":"Laudat","year":"1994","journal-title":"West Indian Med J"},{"issue":"8","key":"10.1016\/j.anai.2024.06.020_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220397","article-title":"Measurement of intestinal permeability using lactulose and mannitol with conventional five hours and shortened two hours urine collection by two different methods: HPAE-PAD and LC-MSMS","volume":"14","author":"Musa","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0043","first-page":"459","article-title":"Food-induced alterations of intestinal permeability in children with cow's milk-sensitive enteropathy and atopic dermatitis","volume":"8","author":"Dupont","year":"1989","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0044","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0091-6749(91)90180-V","article-title":"Identical intestinal permeability changes in children with different clinical manifestations of cow's milk allergy","volume":"88","author":"Jalonen","year":"1991","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0045","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/pai.12106","article-title":"Intestinal permeability in children with food allergy on specific elimination diets","volume":"24","author":"J\u00e4rvinen","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0046","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1046\/j.1365-2133.2003.05287.x","article-title":"Normal keratinocytes express toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis","volume":"148","author":"Baker","year":"2003","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0047","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.jid.5700530","article-title":"Human keratinocytes express functional toll-like receptor 3, 4, 5, and 9","volume":"127","author":"Lebre","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"6640","key":"10.1016\/j.anai.2024.06.020_bib0048","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/41131","article-title":"A human homologue of the Drosophila Toll protein signals activation of adaptive immunity","volume":"388","author":"Medzhitov","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.anai.2024.06.020_bib0049","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.anai.2024.06.020_bib0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fimmu.2012.00287","article-title":"The danger theory: 20 years later","volume":"3","author":"Pradeu","year":"2012","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0051","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaci.2020.11.047","article-title":"Peanut protein acts as a T(H)2 adjuvant by inducing RALDH2 in human antigen-presenting cells","volume":"148","author":"Ruiter","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0052","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/jid.2008.259","article-title":"Atopic dermatitis: a disease caused by innate immune defects?","volume":"129","author":"De Benedetto","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"15","key":"10.1016\/j.anai.2024.06.020_bib0053","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0054","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/25785826.2022.2132683","article-title":"Association of TLR2 and TLR9 gene polymorphisms with atopic dermatitis: a systematic review and meta-analysis with trial sequential analysis","volume":"46","author":"Zhou","year":"2023","journal-title":"Immunol Med"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/all.13622","article-title":"Staphylococcus aureus from atopic dermatitis skin accumulates in the lysosomes of keratinocytes with induction of IL-1\u03b1 secretion via TLR9","volume":"74","author":"Moriwaki","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0056","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/nyas.14654","article-title":"Role of innate immunity and myeloid cells in susceptibility to allergic disease","volume":"1499","author":"Noel","year":"2021","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0057","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaci.2023.11.023","article-title":"How dietary advanced glycation end products could facilitate the occurrence of food allergy","volume":"153","author":"Paparo","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0058","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/nu14020371","article-title":"Receptor mediated effects of advanced glycation end products (AGEs) on innate and adaptative immunity: relevance for food allergy","volume":"14","author":"Briceno Noriega","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0059","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000526528","article-title":"Ovalbumin-induced epithelial activation directs monocyte-derived dendritic cells to instruct Type 2 inflammation in T cells which is differentially modulated by 2\u2032-fucosyllactose and 3-fucosyllactose","volume":"15","author":"Zuurveld","year":"2023","journal-title":"J Innate Immun"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/pai.13246","article-title":"Children with nut allergies have impaired gene expression of toll-like receptors pathway","volume":"31","author":"Poole","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"issue":"7","key":"10.1016\/j.anai.2024.06.020_bib0061","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.it.2019.05.001","article-title":"The healing power of neutrophils","volume":"40","author":"Phillipson","year":"2019","journal-title":"Trends Immunol"},{"issue":"10","key":"10.1016\/j.anai.2024.06.020_bib0062","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/archderm.1976.01630340009002","article-title":"Immunodeficiencies in severe atopic dermatitis. Depressed chemotaxis and lymphocyte transformation","volume":"112","author":"Rogge","year":"1976","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0063","doi-asserted-by":"crossref","first-page":"AB72","DOI":"10.1016\/j.jaci.2023.11.244","article-title":"Extensive serum proteomics in Atopic Dermatitis Subjects reveals novel proteins and pathways relevant for severe disease","volume":"153","author":"Lally","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.06.020_bib0064","doi-asserted-by":"crossref","first-page":"e48448","DOI":"10.7554\/eLife.48448","article-title":"Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis","volume":"8","author":"Walsh","year":"2019","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.anai.2024.06.020_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113148","article-title":"Neutrophil extracellular traps enhance S. aureus skin colonization by oxidative stress induction and downregulation of epidermal barrier genes","volume":"42","author":"Focken","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.anai.2024.06.020_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109805","article-title":"Neutrophil recruitment by CD4 tissue-resident memory T cells induces chronic recurrent inflammation in atopic dermatitis","volume":"256","author":"Zheng","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.anai.2024.06.020_bib0067","doi-asserted-by":"crossref","first-page":"14979","DOI":"10.1038\/ncomms14979","article-title":"Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade","volume":"8","author":"Ouzounova","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0068","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.anai.2024.06.020_bib0069","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1541-7786.MCR-17-0003","article-title":"Infiltrating myeloid cells exert protumorigenic actions via neutrophil elastase","volume":"15","author":"Lerman","year":"2017","journal-title":"Mol Cancer Res"},{"issue":"15","key":"10.1016\/j.anai.2024.06.020_bib0070","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138581","article-title":"Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer","volume":"5","author":"Ugolini","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.anai.2024.06.020_bib0071","article-title":"Skin repair and immunoregulatory effects of myeloid suppressor cells from human cord blood in atopic dermatitis","volume":"14","author":"Kim","year":"2023","journal-title":"Front Immunol"},{"issue":"7993","key":"10.1016\/j.anai.2024.06.020_bib0072","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-023-06797-9","article-title":"An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis","volume":"625","author":"LaMarche","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100631","article-title":"Identifying gene network patterns and associated cellular immune responses in children with or without nut allergy","volume":"15","author":"Lee","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0074","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jaci.2019.10.040","article-title":"Dual transcriptomic and epigenomic study of reaction severity in peanut-allergic children","volume":"145","author":"Do","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.06.020_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876515","article-title":"Alarmin cytokines as central regulators of cutaneous immunity","volume":"13","author":"Hasegawa","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0076","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-immunol-090122-043501","article-title":"The immunobiology and treatment of food allergy","volume":"42","author":"Barshow","year":"2024","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0077","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jaci.2016.01.050","article-title":"Respiratory syncytial virus infection activates IL-13-producing group 2 innate lymphoid cells through thymic stromal lymphopoietin","volume":"138","author":"Stier","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"13","key":"10.1016\/j.anai.2024.06.020_bib0078","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1084\/jem.20130351","article-title":"A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis","volume":"210","author":"Salimi","year":"2013","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0079","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaci.2020.12.628","article-title":"IL-25 (IL-17E) in epithelial immunology and pathophysiology","volume":"148","author":"Borowczyk","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/imr.13323","article-title":"New insights into ILC2 memory","volume":"323","author":"Martinez-Gonzalez","year":"2024","journal-title":"Immunol Rev"},{"key":"10.1016\/j.anai.2024.06.020_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1033904","article-title":"Innate lymphoid cells: more than just immune cells","volume":"13","author":"Xiong","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0082","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.alit.2020.11.007","article-title":"Trained innate lymphoid cells in allergic diseases","volume":"70","author":"Ebihara","year":"2021","journal-title":"Allergol Int"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0083","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/cea.13075","article-title":"IgE promotes type 2 innate lymphoid cells in murine food allergy","volume":"48","author":"Burton","year":"2018","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0084","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2018.05.014","article-title":"A metabolite-triggered tuft cell-ILC2 circuit drives small intestinal remodeling","volume":"174","author":"Schneider","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0085","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.immuni.2019.03.023","article-title":"Mechanical skin injury promotes food anaphylaxis by driving intestinal mast cell expansion","volume":"50","author":"Leyva-Castillo","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0086","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2017.07.003","article-title":"Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis","volume":"88","author":"Mashiko","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100003","article-title":"Dupilumab effects on innate lymphoid cell and helper T cell populations in patients with atopic dermatitis","volume":"1","author":"Imai","year":"2021","journal-title":"JID Innov"},{"issue":"12","key":"10.1016\/j.anai.2024.06.020_bib0088","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41590-021-01067-0","article-title":"Homeostatic IL-13 in healthy skin directs dendritic cell differentiation to promote T(H)2 and inhibit T(H)17 cell polarization","volume":"22","author":"Mayer","year":"2021","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0089","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1189\/jlb.1104631","article-title":"Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy","volume":"78","author":"Feili-Hariri","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.anai.2024.06.020_bib0090","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations (*)","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0091","doi-asserted-by":"crossref","first-page":"adv00099","DOI":"10.2340\/00015555-3452","article-title":"The OX40 axis is associated with both systemic and local involvement in atopic dermatitis","volume":"100","author":"Elsner","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.anai.2024.06.020_bib0092","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122753","article-title":"Inhibition for the treatment of atopic dermatitis-focus on rocatinlimab and amlitelimab","volume":"14","author":"L\u00e9","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0093","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1084\/jem.167.1.43","article-title":"Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors","volume":"167","author":"Yamaguchi","year":"1988","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0094","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1084\/jem.168.3.853","article-title":"Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures","volume":"168","author":"Lebman","year":"1988","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0095","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.4049\/jimmunol.152.3.1094","article-title":"IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells","volume":"152","author":"Punnonen","year":"1994","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0096","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.179.1.135","article-title":"Interleukin 13 is a B cell stimulating factor","volume":"179","author":"Defrance","year":"1994","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0097","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0098","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaci.2023.08.017","article-title":"Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms, and therapeutic targets in atopic diseases","volume":"153","author":"Kim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"10.1016\/j.anai.2024.06.020_bib0099","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1016\/j.cell.2023.10.019","article-title":"S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis","volume":"186","author":"Deng","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.anai.2024.06.020_bib0100","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3389\/fimmu.2020.01740","article-title":"Protease-activated receptor-2 regulates neuro-epidermal communication in atopic dermatitis","volume":"11","author":"Buhl","year":"2020","journal-title":"Front Immunol"},{"issue":"545","key":"10.1016\/j.anai.2024.06.020_bib0101","doi-asserted-by":"crossref","first-page":"eaaz7773","DOI":"10.1126\/scitranslmed.aaz7773","article-title":"Functional role of kallikrein 5 and proteinase-activated receptor 2 in eosinophilic esophagitis","volume":"12","author":"Azouz","year":"2020","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0102","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/eji.202048833","article-title":"IgE in the pathophysiology and therapy of food allergy","volume":"51","author":"Michelet","year":"2021","journal-title":"Eur J Immunol"},{"issue":"6456","key":"10.1016\/j.anai.2024.06.020_bib0103","doi-asserted-by":"crossref","first-page":"eaaw6433","DOI":"10.1126\/science.aaw6433","article-title":"Identification of a T follicular helper cell subset that drives anaphylactic IgE","volume":"365","author":"Gowthaman","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0104","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaci.2022.10.003","article-title":"Mast cells in food allergy: inducing immediate reactions and shaping long-term immunity","volume":"151","author":"Oettgen","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0105","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jaci.2016.06.003","article-title":"Regulatory T cells in allergic diseases","volume":"138","author":"Noval Rivas","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0106","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaci.2008.09.051","article-title":"Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein","volume":"123","author":"Shreffler","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2024.06.020_bib0107","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1084\/jem.20032121","article-title":"Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy","volume":"199","author":"Karlsson","year":"2004","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0108","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2013.12.1037","article-title":"Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3)","volume":"133","author":"Syed","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0109","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaci.2017.04.039","article-title":"Regulatory T-cell populations in children are affected by age and food allergy diagnosis","volume":"140","author":"Prince","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10875-010-9487-1","article-title":"FOXP3, IL-10, and TGF-\u03b2 genes expression in children with IgE-dependent food allergy","volume":"31","author":"Krogulska","year":"2011","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0111","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/all.15512","article-title":"Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T-cell responses in humans","volume":"78","author":"Lozano-Ojalvo","year":"2023","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0112","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4049\/jimmunol.1501271","article-title":"Low-dose IL-2 induces regulatory T cell-mediated control of experimental food allergy","volume":"197","author":"Bonnet","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0113","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0114","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2133.2008.08835.x","article-title":"Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome","volume":"160","author":"Halabi-Tawil","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaci.2005.10.040","article-title":"Absence of T-regulatory cell expression and function in atopic dermatitis skin","volume":"117","author":"Verhagen","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0116","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2500\/aap2007.28.3043","article-title":"FoxP3-expressing T regulatory cells in atopic dermatitis lesions","volume":"28","author":"Caproni","year":"2007","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0117","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1365-2133.2008.08504.x","article-title":"Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides","volume":"158","author":"Fujimura","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0118","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/all.15486","article-title":"Single-cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis","volume":"78","author":"Zhang","year":"2023","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0119","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.anai.2024.02.004","article-title":"Constant vigilance! Managing threats to the skin barrier","volume":"132","author":"Chu","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"397","key":"10.1016\/j.anai.2024.06.020_bib0120","doi-asserted-by":"crossref","first-page":"eaal4651","DOI":"10.1126\/scitranslmed.aal4651","article-title":"Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis","volume":"9","author":"Byrd","year":"2017","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0121","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/all.14489","article-title":"Biofilm propensity of Staphylococcus aureus skin isolates is associated with increased atopic dermatitis severity and barrier dysfunction in the MPAACH pediatric cohort","volume":"76","author":"Gonzalez","year":"2021","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.anai.2024.06.020_bib0122","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jid.2018.03.1517","article-title":"Patients with atopic dermatitis colonized with Staphylococcus aureus Have a distinct phenotype and endotype","volume":"138","author":"Simpson","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0123","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaci.2023.05.026","article-title":"Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment","volume":"152","author":"Simpson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2024.06.020_bib0124","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jid.2017.07.834","article-title":"Skin colonization by Staphylococcus aureus precedes the clinical diagnosis of atopic dermatitis in infancy","volume":"137","author":"Meylan","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0125","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jaci.2016.01.010","article-title":"Food allergy is associated with Staphylococcus aureus colonization in children with atopic dermatitis","volume":"137","author":"Jones","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0126","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jaci.2010.09.002","article-title":"Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the toll-like receptor 2-toll-like receptor 6 pathway","volume":"126","author":"Vu","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0127","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2020.09.023","article-title":"Staphylococcus aureus second immunoglobulin-binding protein drives atopic dermatitis via IL-33","volume":"147","author":"Al Kindi","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0128","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2024.06.020_bib0129","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: the \u201citchy\u201d cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112494","article-title":"Competition between skin antimicrobial peptides and commensal bacteria in type 2 inflammation enables survival of S. aureus","volume":"42","author":"Nakatsuji","year":"2023","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0131","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbrc.2010.07.024","article-title":"Characterization and structure identification of an antimicrobial peptide, hominicin, produced by Staphylococcus hominis MBBL 2-9","volume":"399","author":"Kim","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"378","key":"10.1016\/j.anai.2024.06.020_bib0132","doi-asserted-by":"crossref","first-page":"eaah4680","DOI":"10.1126\/scitranslmed.aah4680","article-title":"Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis","volume":"9","author":"Nakatsuji","year":"2017","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0133","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00930-22","article-title":"The ubiquitous human skin commensal Staphylococcus hominis protects against opportunistic pathogens","volume":"13","author":"Severn","year":"2022","journal-title":"mBio"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0134","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41591-021-01256-2","article-title":"Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial","volume":"27","author":"Nakatsuji","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0135","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.anai.2024.03.010","article-title":"Gut microbiome in the first 1000 days and risk for childhood food allergy","volume":"133","author":"Davis","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0136","first-page":"450","article-title":"New directions in understanding atopic march starting from atopic dermatitis","volume":"9","author":"Maiello","year":"2022","journal-title":"Children (Basel)"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0137","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.anai.2019.03.019","article-title":"The prevalence of atopic dermatitis in children with food allergy","volume":"122","author":"Samady","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0138","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.jaci.2019.06.045","article-title":"Efficacy of the Enquiring About Tolerance (EAT) study among infants at high risk of developing food allergy","volume":"144","author":"Perkin","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2024.06.020_bib0139","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/cea.13486","article-title":"Indoor dust acts as an adjuvant to promote sensitization to peanut through the airway","volume":"49","author":"Smeekens","year":"2019","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0140","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaci.2021.05.035","article-title":"The airway as a route of sensitization to peanut: an update to the dual allergen exposure hypothesis","volume":"148","author":"Kulis","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0141","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.jaci.2021.09.036","article-title":"Longitudinal atopic dermatitis endotypes: an atopic march paradigm that includes Black children","volume":"149","author":"Biagini","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0142","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jaci.2023.01.001","article-title":"Might biologics serve to interrupt the atopic march?","volume":"151","author":"Spergel","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2024.06.020_bib0143","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/all.14304","article-title":"Epicutaneous sensitization in the development of food allergy: what is the evidence and how can this be prevented?","volume":"75","author":"Brough","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2024.06.020_bib0144","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.810067","article-title":"Mouse models of food allergy in the pursuit of novel treatment modalities","volume":"2","author":"Smeekens","year":"2021","journal-title":"Front Allergy"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0145","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.jaci.2008.04.032","article-title":"Epidemiologic risks for food allergy","volume":"121","author":"Lack","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0146","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jaci.2012.02.036","article-title":"Update on risk factors for food allergy","volume":"129","author":"Lack","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0147","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jaci.2017.11.010","article-title":"Food allergy: update on prevention and tolerance","volume":"141","author":"Du Toit","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2024.06.020_bib0148","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa013536","article-title":"Avon Longitudinal Study of Parents and Children Study Team. Factors associated with the development of peanut allergy in childhood","volume":"348","author":"Lack","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0149","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaci.2013.02.034","article-title":"Peanut protein in household dust is related to household peanut consumption and is biologically active","volume":"132","author":"Brough","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0150","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jaci.2008.12.014","article-title":"Household peanut consumption as a risk factor for the development of peanut allergy","volume":"123","author":"Fox","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0151","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jaci.2014.08.011","article-title":"Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-of-function mutations","volume":"134","author":"Brough","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2024.06.020_bib0152","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/all.13143","article-title":"The skin barrier function gene SPINK5 is associated with challenge-proven IgE-mediated food allergy in infants","volume":"72","author":"Ashley","year":"2017","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0153","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2008.08.039","article-title":"Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy","volume":"122","author":"Du Toit","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2024.06.020_bib0154","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1414850","article-title":"Randomized trial of peanut consumption in infants at risk for peanut allergy","volume":"372","author":"Du Toit","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0155","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaci.2018.11.006","article-title":"The atopic march and atopic multimorbidity: many trajectories, many pathways","volume":"143","author":"Paller","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0156","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/all.15518","article-title":"Skin biomarkers predict development of atopic dermatitis in infancy","volume":"78","author":"Rinnov","year":"2023","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0157","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaci.2023.02.013","article-title":"Stratum corneum lipid and cytokine biomarkers at age 2 months predict the future onset of atopic dermatitis","volume":"151","author":"Berdyshev","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0158","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jaci.2024.02.014","article-title":"Skin biomarkers predict the development of food allergy in early life","volume":"153","author":"Berdyshev","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0159","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.alit.2015.09.004","article-title":"Transepidermal water loss measurement during infancy can predict the subsequent development of atopic dermatitis regardless of filaggrin mutations","volume":"65","author":"Horimukai","year":"2016","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0160","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jaip.2019.09.014","article-title":"Predicting skin barrier dysfunction and atopic dermatitis in early infancy","volume":"8","author":"Rehbinder","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0161","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2014.12.013","article-title":"Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year","volume":"135","author":"Kelleher","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0162","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jaci.2015.12.1312","article-title":"Skin barrier impairment at birth predicts food allergy at 2 years of age","volume":"137","author":"Kelleher","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"10.1016\/j.anai.2024.06.020_bib0163","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0164","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"10356","key":"10.1016\/j.anai.2024.06.020_bib0165","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0166","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.anai.2024.06.020_bib0167","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two Phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0168","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0169","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0170","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.06.020_bib0171","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eclinm.2018.12.006","article-title":"A Phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals","volume":"7","author":"Andorf","year":"2019","journal-title":"EClinicalmedicine"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0172","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2024.06.020_bib0173","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0174","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjd.18476","article-title":"Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension","volume":"182","author":"Cork","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0175","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.16928","article-title":"A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy","volume":"35","author":"Paller","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0176","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0177","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase iii open-label extension trial (Liberty AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0178","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0179","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0180","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/all.15591","article-title":"Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients","volume":"78","author":"Spekhorst","year":"2023","journal-title":"Allergy"},{"issue":"22","key":"10.1016\/j.anai.2024.06.020_bib0181","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0182","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0183","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2024.06.020_bib0184","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s13555-023-00942-y","article-title":"Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-week, open-label, Phase 3 study","volume":"13","author":"Paller","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0185","article-title":"Specific allergen immunotherapy for the treatment of atopic eczema","volume":"2","author":"Tam","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0186","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/bjd\/ljad268","article-title":"Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study","volume":"190","author":"Igarashi","year":"2023","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0187","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jaci.2016.05.038","article-title":"Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis","volume":"138","author":"Wang","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0188","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","article-title":"Early-onset pediatric atopic dermatitis is T(H)2 but also T(H)17 polarized in skin","volume":"138","author":"Esaki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0190","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0191","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjd.21631","article-title":"Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis","volume":"187","author":"Laquer","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0192","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","article-title":"Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0193","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0194","article-title":"Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis","volume":"3","author":"Rewerska","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"3","key":"10.1016\/j.anai.2024.06.020_bib0195","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaad.2023.10.026","article-title":"Safety and efficacy of eblasakimab, an interleukin 13 receptor \u03b11 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study","volume":"90","author":"Veverka","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2024.06.020_bib0196","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","article-title":"Disease modification in inflammatory skin disorders: opportunities and challenges","volume":"22","author":"Bieber","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.anai.2024.06.020_bib0197","doi-asserted-by":"crossref","first-page":"adv00731","DOI":"10.2340\/actadv.v102.295","article-title":"Long-term remission of atopic dermatitis after discontinuation of dupilumab","volume":"102","author":"Miyamoto","year":"2022","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.020_bib0198","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"issue":"10372","key":"10.1016\/j.anai.2024.06.020_bib0199","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0200","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.06.020_bib0201","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2024.06.020_bib0202","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaci.2013.11.007","article-title":"Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy","volume":"133","author":"Vickery","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.06.020_bib0203","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jaci.2015.12.1316","article-title":"Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy","volume":"137","author":"Jones","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"10207","key":"10.1016\/j.anai.2024.06.020_bib0204","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","article-title":"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study","volume":"394","author":"Chinthrajah","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0205","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1038\/s41467-022-34222-8","article-title":"CD8(+) T cell differentiation status correlates with the feasibility of sustained unresponsiveness following oral immunotherapy","volume":"13","author":"Kaushik","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.anai.2024.06.020_bib0206","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4168\/aair.2022.14.1.8","article-title":"Origin of allergy from in utero exposures to the postnatal environment","volume":"14","author":"Hui-Beckman","year":"2022","journal-title":"Allergy Asthma Immunol Res"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624003703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624003703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T02:41:04Z","timestamp":1729564864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624003703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":206,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1081120624003703"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.06.020","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atopic dermatitis and IgE-mediated food allergy","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}